-
1
-
-
84992358035
-
The cardiovascular biology of glucagon-like peptide-1
-
Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab 2016;24:15-30.
-
(2016)
Cell Metab
, vol.24
, pp. 15-30
-
-
Drucker, D.J.1
-
2
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
-
(2016)
N Engl J Med
, vol.375
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
-
3
-
-
84994813253
-
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
-
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44.
-
(2016)
N Engl J Med
, vol.375
, pp. 1834-1844
-
-
Marso, S.P.1
Bain, S.C.2
Consoli, A.3
-
4
-
-
85030448557
-
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
-
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228-39.
-
(2017)
N Engl J Med
, vol.377
, pp. 1228-1239
-
-
Holman, R.R.1
Bethel, M.A.2
Mentz, R.J.3
-
5
-
-
84948740668
-
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
-
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.
-
(2015)
N Engl J Med
, vol.373
, pp. 2247-2257
-
-
Pfeffer, M.A.1
Claggett, B.2
Diaz, R.3
-
7
-
-
84898919428
-
The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy
-
Varadhan L, Humphreys T, Walker AB, et al. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract 2014;103:e37-e39.
-
(2014)
Diabetes Res Clin Pract
, vol.103
, pp. e37-e39
-
-
Varadhan, L.1
Humphreys, T.2
Walker, A.B.3
-
8
-
-
85019559864
-
GLP-1R as a target for the treatment of diabetic retinopathy: Friend or foe?
-
Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes 2017;66:1453-60.
-
(2017)
Diabetes
, vol.66
, pp. 1453-1460
-
-
Simó, R.1
Hernández, C.2
-
9
-
-
84962147366
-
Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes
-
Hernández C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 2016;65:172-87.
-
(2016)
Diabetes
, vol.65
, pp. 172-187
-
-
Hernández, C.1
Bogdanov, P.2
Corraliza, L.3
-
10
-
-
85026802542
-
Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes
-
Hernández C, Bogdanov P, Solà-Adell C, et al. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia 2017;60:2285-98.
-
(2017)
Diabetologia
, vol.60
, pp. 2285-2298
-
-
Hernández, C.1
Bogdanov, P.2
Solà-Adell, C.3
-
11
-
-
85026922718
-
Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-Analysis of randomized controlled trials
-
Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-Analysis of randomized controlled trials. Acta Diabetol 2017;54:933-41.
-
(2017)
Acta Diabetol
, vol.54
, pp. 933-941
-
-
Dicembrini, I.1
Nreu, B.2
Scatena, A.3
-
12
-
-
85025080031
-
Reality and truth: Balancing the hope and the hype of real-world evidence
-
Patel A, Billot L, Reality BL. Reality and truth: balancing the hope and the hype of real-world evidence. Circulation 2017;136:260-2.
-
(2017)
Circulation
, vol.136
, pp. 260-262
-
-
Patel, A.1
Billot, L.2
Reality, B.L.3
-
13
-
-
85024835007
-
SGTL2 inhibitors and amputations in the US FDA adverse event reporting system
-
Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol 2017;5:680-1.
-
(2017)
Lancet Diabetes Endocrinol
, vol.5
, pp. 680-681
-
-
Fadini, G.P.1
Avogaro, A.2
-
14
-
-
85023777061
-
Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
-
(2017)
N Engl J Med
, vol.377
, pp. 644-657
-
-
Neal, B.1
Perkovic, V.2
Mahaffey, K.W.3
-
15
-
-
34447520376
-
Novel statistical tools for monitoring the safety of marketed drugs
-
Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007;82:157-66.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 157-166
-
-
Almenoff, J.S.1
Pattishall, E.N.2
Gibbs, T.G.3
-
16
-
-
84978372329
-
Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data
-
Sarangdhar M, Tabar S, Schmidt C, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol 2016;34:697-700.
-
(2016)
Nat Biotechnol
, vol.34
, pp. 697-700
-
-
Sarangdhar, M.1
Tabar, S.2
Schmidt, C.3
-
17
-
-
2642668188
-
Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study
-
The Kroc Collaborative Study Group. The Kroc Collaborative Study Group
-
The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group. JAMA 1988;260:37-41.
-
(1988)
JAMA
, vol.260
, pp. 37-41
-
-
-
18
-
-
85041694897
-
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
-
Epub ahead of print 27 Nov 2017
-
Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2017. 10.1111/dom.13172 (Epub ahead of print 27 Nov 2017).
-
(2017)
Diabetes Obes Metab
-
-
Vilsbøll, T.1
Bain, S.C.2
Leiter, L.A.3
-
19
-
-
85019269077
-
SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA adverse event reporting system
-
Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 2017;60:1385-9.
-
(2017)
Diabetologia
, vol.60
, pp. 1385-1389
-
-
Fadini, G.P.1
Bonora, B.M.2
Avogaro, A.3
-
20
-
-
69549088241
-
Regression from prediabetes to normal glucose regulation in the diabetes prevention program
-
Perreault L, Kahn SE, Christophi CA, et al. Regression from prediabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 2009;32:1583-8.
-
(2009)
Diabetes Care
, vol.32
, pp. 1583-1588
-
-
Perreault, L.1
Kahn, S.E.2
Christophi, C.A.3
-
21
-
-
0037097039
-
Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial
-
Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
-
(2002)
Lancet
, vol.359
, pp. 2072-2077
-
-
Chiasson, J.L.1
Josse, R.G.2
Gomis, R.3
-
22
-
-
84936166069
-
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
-
Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.
-
(2015)
N Engl J Med
, vol.373
, pp. 11-22
-
-
Pi-Sunyer, X.1
Astrup, A.2
Fujioka, K.3
-
23
-
-
84858414156
-
Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: Retrospective analysis
-
Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: Retrospective analysis. BMJ 2012;344:e874.
-
(2012)
BMJ
, vol.344
, pp. e874
-
-
Thomas, R.L.1
Dunstan, F.2
Luzio, S.D.3
-
24
-
-
85021835588
-
Sodium-glucose co-Transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature
-
Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-Transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab 2018;20.
-
(2018)
Diabetes Obes Metab
, pp. 20
-
-
Bonora, B.M.1
Avogaro, A.2
Fadini, G.P.3
|